Evidence map›Paper›PMID 39310595›Full record

ArticleCureus2024

A Case of Liver Injury Immediately After Initiation of Triple Therapy in a Patient With BRAF V600E Mutation-Positive Colorectal Cancer.

Yuka Aimono, Atsushi Ohkawara, Tatsunori Ogawa, Takahiro Yagisawa, Akihiro Tamura

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuka AimonoPharmacy, Hitachi General Hospital, Hitachi, JPN.
Atsushi OhkawaraGastroenterology, Hitachi General Hospital, Hitachi, JPN.
Tatsunori OgawaPharmacy, Hitachi General Hospital, Hitachi, JPN.
Takahiro YagisawaPharmacy, Hitachi General Hospital, Hitachi, JPN.
Akihiro TamuraPharmacy, Hitachi General Hospital, Hitachi, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The combination therapy of binimetinib, encorafenib, and cetuximab ("triplet regimen") was approved in Japan in November 2020 for the second-line treatment of BRAF V600E mutation-positive colorectal cancer. In this study, we encountered a patient who developed a liver injury requiring drug withdrawal on day eight of the triplet regimen administration. The protocol for the international phase III study did not specify blood and biochemical tests on day eight. Hepatic failure occurred in 45.9% (222/484) of the patients within three months, but no specific timing of onset was reported. Since it is important to disseminate novel adverse events to the public, we report the results of this study based on a literature review.

Indexed as

binimetinibcetuximabencorafenibliver injurypharmaceutical service

Identifiers

PMID39310595
PMCPMC11415221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.